Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Damora Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- −1 vs. Q4 2021
- Shares held
- 9.57M
- −491.6K (−4.9%) vs. Q4 2021
- Total value
- $21.0M
- −$9.43M (−30.9%) vs. Q4 2021
- New holders
- 2
- 4 more added
- Sold out
- 3
- 8 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 4,090,937 | $9.00M | 0.15% | 00.0% | Unchanged |
| Novo Holdings A/S | 2,497,791 | $5.50M | 0.29% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 1,020,238 | $2.25M | 0.17% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 724,523 | $1.59M | 0.00% | −35,233−4.6% | Reduced |
| Renaissance Technologies LLC | 226,164 | $498.0K | 0.00% | −4,036−1.8% | Reduced |
| Laurion Capital Management LP | 190,652 | $419.0K | 0.01% | −4,200−2.2% | Reduced |
| Bridgeway Capital Management, LLC | 183,100 | $403.0K | 0.01% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 143,700 | $316.0K | 0.00% | −140,200−49.4% | Reduced |
| Two Sigma Investments, LP | 143,666 | $316.0K | 0.00% | −113,152−44.1% | Reduced |
| Geode Capital Management, LLC | 97,185 | $213.0K | 0.00% | +1,049+1.1% | Added |
| Marquette Asset Management, LLC | 45,765 | $101.0K | 0.02% | +9,265+25.4% | Added |
| State Street Corp | 43,006 | $95.0K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 36,313 | $80.0K | 0.00% | −1,659−4.4% | Reduced |
| Millennium Management LLC | 28,881 | $64.0K | 0.00% | +1,125+4.1% | Added |
| Federated Hermes, Inc. | 26,000 | $57.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 25,708 | $57.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 19,006 | $42.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 14,164 | $31.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 2,977 | $6.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,495 | $5.00K | 0.00% | −4,248−63.0% | Reduced |
| JPMorgan Chase & Co | 1,766 | $4.00K | 0.00% | +1,766 | New |
| Citigroup Inc | 242 | $1.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 563 | $1.00K | 0.00% | +562+56,200.0% | Added |
| Tower Research Capital LLC (TRC) | 406 | $1.00K | 0.00% | +406 | New |
| Simplex Trading, LLC | 74 | $0 | 0.00% | −480−86.6% | Reduced |
| Anson Funds Management LP | 0 | $0 | 0.00% | −183,530−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −15,964−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −3,119−100.0% | Sold out |